Investment Thesis
Apimeds is a pre-revenue pharmaceutical company with severe cash burn and negative profitability. The company is hemorrhaging cash at -$5.1M operating cash flow with only $7.0M in reserves, creating critical runway concerns. Without demonstrated commercial traction or clear path to profitability, the company faces existential funding risk.
APUS Strengths
- Strong current ratio of 8.34x provides near-term liquidity buffer
- Zero debt burden eliminates solvency pressure from leverage
- Stockholders equity of $8.2M provides some balance sheet cushion
APUS Risks
- Pre-revenue model with no commercial product sales indicates zero market validation
- Operating cash burn of -$5.1M with only ~1.4 years of cash runway at current burn rate
- Negative ROE of -59.4% and ROA of -52.4% indicate severe value destruction
- No insider trading activity in 90 days suggests lack of insider confidence
- Development-stage pharmaceutical with unproven product-market fit and regulatory approval uncertainty
Key Metrics to Watch
- Monthly cash burn rate and runway duration
- Progress toward revenue generation or regulatory milestones
- Changes in operating cash flow trajectory
- Debt issuance or equity dilution financing activity
- Clinical trial progress and FDA approval status
APUS Financial Metrics
APUS Profitability Ratios
APUS Balance Sheet & Liquidity
APUS 5-Year Financial Trend
5-Year Trend Summary: Apimeds Pharmaceuticals US, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
APUS Growth Metrics (YoY)
APUS Capital Allocation
APUS SEC Filings
Access official SEC EDGAR filings for Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525)